Акромегалия: современные достижения в диагностике и лечении

Акромегалия -– тяжелое нейроэндокринное заболевание, сопровождающееся развитием многообразных осложнений, приводящих к ранней инвалидизации и сокращению продолжительности жизни. Только своевременное выявление заболевания и применение современных методов лечения позволяют добиться надежного результата и оптимизировать качество жизни больных. В настоящее время консенсусом 2010 г. определены оптимальные лабораторные тесты как с целью диагностики данного заболевания, так и мониторинга после проведения различных видов терапии. Это оральный глюкозотолерантный тест (ОГТТ) с определением уровня СТГ, а также исследование уровня общего ИРФ1. Принято решение считать, что заболевание контролируемо, если базальный или случайный уровень СТГ составляет менее 1 нг/мл, минимальный уровень СТГ в ходе ОГТТ - менее 0,4 нг/мл и показатель ИРФ1 соответствует норме. Оптимальным методом визуализации аденомы гипофиза признана МРТ с контрастным усилением. Последние десятилетия разработаны эффективные методы лечения акромегалии, включая транссфеноидальную аденомэктомию с применением высокотехнологичного нейрохирургического оснащения, узкофокусированные методы лучевой терапии, а также современные средства медикаментозной терапии, включая длительно действующие мультилигандные аналоги соматостатина, антагонисты рецепторов гормона роста.

акромегалия, современные методы диагностики, транссфеноидальная аденомэктомия, медикаментозная терапия

1. Holdaway I.M., Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999;2:1:29-41.

2. Bates A.S., Van't Hoff W., Jones J.M. et al. Does treatment of acromegaly affect life expectancy? Metabolism 1995;44:Suppl 1:1-5.

3. Bates A.S., Van't Hoff W., Jones J.M., Clayton R.N. An audit of outcome of treatment in acromegaly. Q J Med 1993;86:5:293-299.

4. Holdaway I.M., Rajasoorya R.C., Gamble G.D. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89:2:667-674.

5. Ayuk J., Clayton R.N., Holder G. et al. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004;89:4:1613-1617.

6. Biermasz N.R, Dekker F.W., Pereira A.M. et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 2004;89:6:2789-2796.

7. Swearingen B., Barker F.G., Katznelson L. et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:10:3419-3426.

8. Barkan A. Controversies in the diagnosis and therapy of acromegaly. Endocrinologist 1997;7:300-307.

9. Helen E. Turner. Clinical features, investigation and complications of acromegaly. Handbook of acromegaly. Ed. J. Wass. Bioscientifica Bristol UK 2001;19-28.

10. Acromegaly. A handbook of history, current therapy and future prospects. Edited by JAH Wass. BioScientifica Bristol UK 2009.

11. Lampron A., Feelders R.A., Hofland L.J. et al. Abberant Expression of Glucose-Dependent Insulinotropic Polypeptide Receptor (DIPR) in Growth Hormone-Secreting Adenomas with Paradoxical Increase in GH Following Oral Glucose Load. ENDO 08, 90th Annual Meeting, San Francisco. Abstract book 3-739;792.

12. Arafat A.M., Mőhlig M., Weickert M.O. et al. Growth hormone response during OGTT: the impact of assay method, gender and BMI on the estimaion of reference values in patients with acromegaly and in healthy controls. 9th European Congress of Endocrinology. 2007, 28 April-2 May. Budapes Hungary Endocrine Abstracts 2007;14:OC8.1.

13. Acromegaly - pathology, diagnosis and treatment. Taylor and Francis group LLC USA 2005;73-95.

14. Medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. AACE Endocrine Pract 2004;10:3:213-225.

15. Giustina A., Chanson P., Bronstein M.D. et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010;95:7:3141-3148.

16. Giustina A., Barkan A., Casanueva F.F. et al. Criteria for cure of acromensgaly: a consensus statement. J Clin Endocrinol Metab 2000;85:2:526-529.

17. Fukuda I., Hizuka N., Kurimoto M. et al. The influences of the standardization of GH assay on the remission criteria for acromegaly. 90th Annual Meeting. San Francisco 2008; Abstract book:2-717;578.

18. Воронцов А.В. Магнитно-резонансная томография в диагностике патологии гипоталамо-гипофизарной системы и надпочечников: Автореф. дис. ... д-ра мед. наук. М 2001.

19. John A. Jane Jr., Edward R. Laws. History of acromegaly. Handbook of acromegaly. Ed. J. Wass. Bioscientifica UK Bristol 2001;3-15.

20. Melmed S., Casanueva F., Cavagnini F. et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005;153:737-740.

21. Melmed S., Casanueva F.F., Cavagnini F. et al. Consensus. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002;87:9:4054-4058.

22. Colao A., Attanasio R., Pivonello R. et al. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2006;91:1:85-92.

23. Barkan A. Current management of Acromegaly. Program and Abstracts. SY10-4-1, S280.14–th International Congress of Endocrinology (ICE2010). Endocr J 2010;57:Suppl 2.

24. Kazunori A. Short and long term effects of transsphenoidal surgery on growth hormone producing pituitary adenomas: based on the experiences with 290 patients. March 2010, SY10-4-2, S280.14th International Congress of Endocrinology (ICE2010). Endocr J 2010;57:Suppl 2.

25. Bonert V.S., Carmichael J.D., Barnett P., Melmed S. 10 year treatment outcomes in 100 patients with Acromegaly. Abstract book. 90th Annual Meeting. San Francisco 2008;2-738:583.

26. Cozzi R., Lasio G., Felisati G., Attanasio R. Transphenoidal adenomectomy by endoscopic technique in Acromegaly: a single-center experience. Abstract book. 90th Annual Meeting. San Francisco 2008;2-741;584.

27. Tomlinson J.W., Holden N., Hills R.K. et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001;357:425-431.

28. Lecumberri B., Estrada F.J., Garsia-Uria J. et al. Evaluation of Verbal Memory and Executive Functions in 66 Acromegalic patients treated with or without Conventional Radiotherapy after Transsphenoidal Surgery. 90th Annual Meeting. San Fransisco 2008;2-725.

29. Kirklin O.L., Wilder R.M. Follicular hormone administered in acromegaly. Mayo Clin Proceedings 1936;11:121-125.

30. McCullagh E.R., Beck J.C., Schaffenburg C.A. Control of diabetes and other features of acromegaly following treatment with estrogens. Diabetes 1955;4:13-23.

31. Mintz D.H., Finster J.L., Josimovich J.B. Effect of estrogen-therapy on carbohydrate metabolism in acromegaly. J Clin Endocrinol Metab 1967;27:1321-1327.

32. Schwartz E., Echemendia E., Schiffer M., Panariello V.A. Mechanism of estrogen action in acromegaly. J Clin Invest 1969;48:260-270.

33. Liuzzi A., Chiodini P.G., Botalla L. et al. Inhibitory effect of l-dopa on GH release in acromegalic patients. J Clin Endocrinol Metab 1972;35:941-943.

34. Liuzzi A., Chiodini P.G., Botalla L. et al. Decreased plasma growth hormone (GH) levels in acromegalics following CB 154 (2-Br-alpha ergocryptine) administration. J Clin Endocrinol Metab 1974;38:910-912.

35. Liuzzi A., Chiodini P.G., Botalla L. et al. Growth hormone (GH)-releasing activity of TRH and GH-lowering effect of dopaminergic drugs in acromegaly: homogeneity in the two responses. J Clin Endocrinol Metab 1974;39:871-876.

36. Thorner M.O., Chait A., Aitken M. et al. Bromocriptine treatment of Acromegaly. Br Med J 1975;1:299-303.

37. Abs R., Verhelst J., Matter D. et al. Cabergoline In the treatment of acromegaly: A study in 64 patients. J Сlin Endocrinol Metab 1998;83:2:374-378.

38. Jackson S.N., Fowler J., Howlett T.A. Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin Endocrinol 1997;46:6:745-749.

39. Vale W., Brazeau P., Grant G. et al. Premieres observations sur le mode d'action de la somatostatine un facteur hypothalamique qui inhibe la secretion de I'hormone do auissnncc. СR Acad Sci (Paris) 1972;275:2913-2915.

40. Plewe G., Beyer J., Krause U. et al. Long-acting and selective supression of GH secretion by somatostatin analog SMS 201-995 in Acromegaly. Lancet 1984;2:782-787.

41. Murray R.D., Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of Acromegaly. J Clin Endocrinol Metab 2008;93:8:2957-2968.

42. Abe T., Ludecke D.K. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 2001;145:137-145.

43. Arosio M., Macchelli S., Rossi C.M. et al. Effects of treatment with octreotide in acromegalic patients - a multicenter Italian study. Eur J Endocrinol 1995;133:430-439.

44. Bevan J. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005;90:3:1856-1863.

45. Newman C.B., Melmed S., George A. et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998;83:9:3034-3040.

46. Colao A., Pivonello R., Rosato F. et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol 2006;64:342-351.

47. Cozzi R., Attanasio R., Montini M. et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results. J Clin Endocrinol Metab 2003;88:7:3090-3098.

48. Davies P.H., Stewart S.E., Lancranjan I. et al. Long-term therapy with long acting octreotide (Sandostatin-LAR) for the management of Acromegaly. Clin Endocrinol 1998;48:311-316.

49. Freda Pamela U., Katznelson L., van der Lely A.J. et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005;90:8:4465-4473.

50. Lancranjan I., Atkinson A. The Sandostatin LAR Group. Results of a European Multicentre study with sandostatin LAR in acromegaly patients. Pituitary1999;1:105-114.

51. Verhelst J.A., Pedroncelli A.M., Abs R. et al. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol 2000;143:577-584.

52. Sheppard M.C. Primary medical therapy for acromegaly. Clin Endocrinol 2003;58:387-399.

53. Cozzi R., Montini M., Attanasio R. et al. Primary treatment of acromegaly with octreotide LAR: a long–term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006;91:4:1397-1403.

54. Caron P., Beckers A., Cullen D.R. et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002;87:99:104.

55. Pawlikowski M., Pisarek H., Kunert-Radek J., Radek M. Somatostatin receptors in GH-secreting pituitary adenomas: relationship with the response to octreotide. Abstract book. 90th Annual Meeting. San Francisco 2008;2-714;577.

56. Takei M., Kajiya H., Tahara S. et al. The correlation between the expression of somatostatin receptors in pathology specimens from acromegalic patients and the percent suppression of GH levels in the octreotide suppression test. Abstract book. 90th Annual Meeting. San Francisco 2008;2-715;577.

57. Muller A.F., Kopchick J.J., Flyvbjerg A. et al. Clinical review 166. Growth Hormone Receptor Antagonists. J Clin Endocrinol Metab 2004;89:4:1503-1511.

58. Strasburger Ch. Use of pegvisomant in clinical practice: what can we learn from ACROSTUDY? An abstract book at the 9th European congress of endocrinology. Program Agenda 2007.

59. Jorgensen J.O. Glucose homeostasis and pegvisomant treatment - overview from published data. An abstract book at the 9th European congress of endocrinology. Program Agenda 2007.

60. Parcinson C. Pegvisomant (Somavert): the first growth hormone-receptor antagonist for the treatment of acromegaly. Eur J Hosp Pharm 2004;1:112-119.

61. Rose D.R., Clemmons D.R. Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm IGF Res 2002;12:418-424.

62. Martino M.C., AuriemmaR.S., Brevetti G. et al. Effect of GH receptor antagonist pegvisomant on cardiovascular risk and atherosclerosis in acromegalic patients resistant to somatostatin analogues. 9th European Congress of Endocrinology. Budapest Hungary Endocrine Abstracts 2007;14:OC8.2.

63. Auriemma R.S., De Martino M.C., Galdiero M. Cardiac performance after long-term treatment with Pegvisomant in patients with acromegaly: a radionuclide angiography study. 10th European congress of endocrinology, 3-7 May 2008. Berlin (Germany). Endocrine Abstracts 2008;16:OC1.5.

64. Trainer P. The use of pegvisomant as either monotherapy or combination with Octreotide LAR in patients with acromegaly uncontrolled by Octreotide LAR - results from a prospective clinical trial. Medical treatment of acromegaly: current evidence and new insights. An abstract book at the 9th European congress of endocrinology. Program Agenda 2007.

65. Neggers S., Van Aken M., Janssen J. et al. Combined treatment for acromegaly with long-acting somatostatin analogues and pegvisomant weekly: long-term safety after 21,6 months of follow-up. HTS1.2 Abstract book. 13th Meeting of ENEA. Antalya (Turkey) 2008;85.

66. Petersenn S., Glusman J., Unger N., Mann C. The effects of pasireotide (SOM230) on glucose metadolism and growth hormone (GH) nadir during oral glucose tolerance test (OGTT) in 12 patients with acromegaly from a Phase II study. 9th European congress of endocrinology, 28 April-2 May 2007. Budapest (Hungary). Endocrine Abstracts 2007;14:565.

67. Petersenn S., Bollerslev J., Arafat A.M. et al. Pasireotide LAR Shows Efficacy in Patients with Acromegaly: Interim Results from a Randomized, Multicenter, Pharmacokinetic/Pharmacodynamic, Phase I Study. ENDO 08, 90th Annual Meeting. San Francisco 2008;Abstract book:OR41-5:149.

68. Bronsttein M., Gu F., Shen C. C et al. A randomized, blinded, multictnter, Fhase III study to assess the efficacy, safety of pasireotide LAR versus octreotide LAR in patients with active Acromegaly. OC-6.1. 14th congress of ENEA. Liege (Belgium) 2010.

69. De Bruin C., Van DerHoek J., Waaijers M. et al. Functional characterization of somatostatin chimeric molecule BIM-23A760. HTS2.5. Abstract book. 13th Meeting of ENEA. Antalya (Turkey) 2008;91.

70. Froehlich J., Llopis M.C., Ramis J. et al. Safety, pharmacokinetics and pharmacodinamics after subcutaneous administration of BIM 23A760, a chimeric compound combining dohaminergic agonist and somatostatin analog, in healthy male volunteers. 91st Annual Meeting of the Endocrine Society. Washington DC (USA) 2009;3-685.

71. Kaminski G., Szalus N., Zielinski G. et al. Inoperable pituitary tumours treated with 90Y-DOTA-TATE - initial results. 9th European Congress of Endocrinology, 2007, 28 April-2 May, Budapest, Hungary Endocrine Abstracts, April 2007, Vol. 14. Abstract book. 90th Annual Meeting. San Francisco 2008.

72. Vitale G., De Herder W.W., Van Koetsveld P.M. et al. Potential role of interferon-[bet] in the treatment of human pituitary adenomas. HTS1.3. Abstract book. 13th Meeting of ENEA. Antalya (Turkey) 2008;86.

73. Zatelli M.C., Filieri C., Tagliat F. et al. Everolimus differently affect cell viability of human pituitary adenomas in vitro. OC6.2. Abstract book. 13th Meeting of ENEA. Antalya (Turkey) 2008;67.